keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Bivalirudin (BG-8967) 是一种直接凝血酶(thrombin)抑制剂,是一种肽类抗凝剂,可在侵入性心脏病,特别是在经皮冠状动脉介入中用于抗凝。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 268 | 现货 | ||
10 mg | ¥ 380 | 现货 | ||
25 mg | ¥ 625 | 现货 | ||
50 mg | ¥ 918 | 现货 | ||
100 mg | ¥ 1,350 | 现货 |
产品描述 | Bivalirudin (BG-8967) is a reversible inhibitor of α- and ζ-thrombin (Kis = 2.56 and 1.84 nM, respectively), enzymes that exhibit high fibrinogen-clotting activities. |
靶点活性 | α-thrombin:2.56 nM (Ki, cell free) |
体外活性 | Whereas 0.1 microM-hirudin and 0.1 microM-Bivalirudin (i.e. less than 10% of the concentration of prothrombin in plasma) inhibited Factor X, Factor V, and prothrombin activation. Concentrations of hirudin and hirulog-1 equimolar to and 5 times greater than those of alpha-thrombin respectively abrogated Factor V activation by exogenous alpha-thrombin [2]. |
体内活性 | Deposition in aspirin-treated groups receiving low-, medium-, and high-dose Bivalirudin decreased in a dose-dependent manner by 37%, 44%, and 56%, respectively. As the dose of Bivalirudin was increased, the plasma Bivalirudin levels and activated partial thromboplastin time ratios (final: initial) also increased in a dose-dependent manner. The mean plasma Bivalirudin levels ranged from 0.74 micrograms/ml in the low-dose Bivalirudin group to 2.55 micrograms/ml in the high-dose Bivalirudin group, and the corresponding activated partial thromboplastin time ratios were 1.5 and 3.3 [3]. |
动物实验 | Animals were randomly assigned to one of five groups: control (no aspirin or hirulog); aspirin alone (10 mg/kg); aspirin plus low-dose hirulog (0.2 mg/kg bolus followed by 0.5 mg/kg/hr); aspirin plus medium-dose hirulog (0.4 mg/kg bolus followed by 1.0 mg/kg/hr); or aspirin plus high-dose hirulog (0.6 mg/kg bolus followed by 1.5 mg/kg/hr). Hirulog was infused before surgery and continued until termination of the experiment 30 minutes after endarterectomy [3]. |
别名 | BG-8967, 比伐卢定, Hirulog-1 |
分子量 | 2180.29 |
分子式 | C98H138N24O33 |
CAS No. | 128270-60-0 |
keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mM
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 0.4587 mL | 2.2933 mL | 4.5865 mL | 11.4664 mL |
5 mM | 0.0917 mL | 0.4587 mL | 0.9173 mL | 2.2933 mL | |
10 mM | 0.0459 mL | 0.2293 mL | 0.4587 mL | 1.1466 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Bivalirudin 128270-60-0 Proteases/Proteasome Thrombin BG8967 anticoagulation invasive peptide coronary Inhibitor platelets BG-8967 percutaneous anticoagulant 比伐卢定 Hirulog-1 inhibit cardiology BG 8967 inhibitor